MedTrace Logo

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

NCT02017613 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2016-06-24

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.

Conditions

Interventions

DRUG

RP6530

Escalating doses starting at 25 mg BID

Sponsors & Collaborators

  • Rhizen Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Andrés JM Ferreri, MD · Ospedale San Raffaele s.r.l.

  • Carmelo Carlo-stella, MD · Humanitas Clinical and Research Centre

  • Richard Delarue, MD · Hopital Necker-Enfants Malades

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • France
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017613 on ClinicalTrials.gov